Vericel Gets FDA Approval Of NexoBrid For The Treatment Of Pediatric Patients With Severe Thermal Burns
Portfolio Pulse from Benzinga Newsdesk
Vericel Corporation (NASDAQ:VCEL) has received FDA approval for the pediatric use of NexoBrid for treating severe thermal burns. This approval expands the target customer base to include approximately 20 pediatric burn centers.
August 15, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vericel Corporation has received FDA approval for the pediatric use of NexoBrid, expanding its market to include 20 pediatric burn centers.
The FDA approval for pediatric use of NexoBrid significantly expands Vericel's market reach, potentially increasing revenue and market share. This is a positive development for the company's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100